Potassium%2525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520chloride

# Potassium Chloride ## Overview Potassium chloride (KCl) is an electrolyte essential for nerve conduction, muscle contraction, and maintaining acid-base balance. It is available in oral and intravenous formulations. ## Primary Indications * Treatment and prevention of hypokalemia. * Potassium supplementation in patients receiving diuretics that deplete potassium, or in conditions associated with significant potassium loss. ## Adult Dosing * **Oral:** * **Treatment of hypokalemia:** Typically 20-100 mEq per day, divided into 2-4 doses. Doses up to 200 mEq/day have been used in severe cases. * **Prevention of hypokalemia:** Typically 10-20 mEq per day. * *Note:* Maximum single oral dose is generally limited to 40 mEq to minimize gastrointestinal adverse effects. Daily doses depend on electrolyte status and clinical indication. * **Intravenous (IV):** * **Treatment of hypokalemia:** * Mild to moderate hypokalemia (serum K+ 2.5-3.5 mEq/L): 20-40 mEq added to a large volume IV fluid (e.g., 1 L of 0.9% NaCl or 5% dextrose), infused at a rate not exceeding 10 mEq/hour. * Severe hypokalemia or cardiac arrhythmias (serum K+ <2.5 mEq/L): May require higher doses (e.g., up to 20-40 mEq per hour) administered via a central venous catheter. **This is a critical care intervention and requires very close monitoring.** * **Maximum daily IV dose:** Generally not to exceed 400 mEq per 24 hours, but individualize based on response and tolerance. * *Note:* **IV potassium administration must be done with extreme caution due to the risk of cardiac arrest.** The concentration of IV potassium should generally not exceed 40 mEq/L in peripheral IV lines or 80 mEq/L in central venous lines to minimize phlebitis and pain. ## Pediatric Dosing * **Oral:** * **Treatment of hypokalemia:** 2-5 mEq/kg/day, divided into 2-4 doses. Maximum daily dose typically 40 mEq/day. * **Prevention of hypokalemia:** 1-2 mEq/kg/day, divided into 1-2 doses. Maximum daily dose typically 20 mEq/day. * **Intravenous (IV):** * **Treatment of hypokalemia:** Generally 0.5-1 mEq/kg per dose, infused at a rate not exceeding 10 mEq/hour. Higher rates may be used in life-threatening situations with continuous cardiac monitoring. * *Note:* **IV potassium administration in pediatrics is particularly hazardous.** Concentrations should not exceed 40 mEq/L in peripheral lines. ## Dose Adjustments * **Renal Impairment:** Dose reduction is essential. Potassium is primarily excreted by the kidneys. Impaired renal function significantly increases the risk of hyperkalemia. Monitor electrolytes closely. In severe renal impairment, potassium supplementation may be contraindicated. ## Contraindications * Hyperkalemia (serum K+ >5.0 mEq/L). * Conditions leading to excessive potassium retention, such as untreated Addison's disease, acute dehydration, severe renal impairment, or anuria. * Certain gastrointestinal conditions (e.g., esophageal obstruction, delayed gastric emptying, intestinal strictures, peptic ulceration) when using oral solid dosage forms due to risk of ulceration. ## Adverse Effects * **Gastrointestinal (oral):** Nausea, vomiting, diarrhea, abdominal pain, gastrointestinal bleeding, ulceration, perforation. * **Cardiovascular (IV):** Hyperkalemia leading to cardiac arrhythmias, conduction abnormalities, bradycardia, hypotension, cardiac arrest. * **Other:** Hyperkalemia can also cause muscle weakness, flaccid paralysis, and mental confusion. ## Key Drug Interactions * **ACE inhibitors, ARBs, Potassium-sparing diuretics (e.g., spironolactone, amiloride, triamterene), NSAIDs, Heparin, Trimethoprim:** Increased risk of hyperkalemia. * **Aldosterone antagonists (e.g., eplerenone):** Increased risk of hyperkalemia. * **Digitalis glycosides:** Hyperkalemia can potentiate digitalis toxicity; hypokalemia can increase sensitivity to digitalis. ## Monitoring * **Serum potassium levels:** Frequently, especially during initiation of therapy, dose changes, or in patients with renal impairment or conditions predisposing to potassium imbalance. * **Renal function (BUN, creatinine):** Assess baseline and monitor periodically. * **ECG:** Particularly important during rapid IV potassium administration or in patients with suspected hyperkalemia. * **Urine output:** Ensure adequate renal perfusion. * **Signs and symptoms of hypokalemia and hyperkalemia.** ## Clinical Pearls * Oral potassium supplements can cause significant gastrointestinal upset. Liquid formulations or enteric-coated tablets may improve tolerability. Administering with meals can also help. * Dilute IV potassium appropriately to prevent phlebitis, pain, and cardiac complications. **Never administer IV potassium as a bolus injection.** * Hypokalemia is often associated with other electrolyte abnormalities (e.g., magnesium). * Always confirm the concentration and rate of infusion for IV potassium with another licensed professional. * Dosing is highly individualized based on serum potassium levels, clinical presentation, and renal function. *** *Disclaimer: This information is intended for educational purposes and does not substitute for professional medical advice. Always consult the most current prescribing information and relevant clinical guidelines for definitive patient care decisions.*